Sichuan Hebang Biotechnology Co Ltd (603077) — Working Capital to Net Assets Ratio
Sichuan Hebang Biotechnology Co Ltd (603077) has a Working Capital to Net Assets ratio of 50.8% as of March 2026. Working capital of CN¥9.23 Billion (current assets of CN¥12.47 Billion minus current liabilities of CN¥3.24 Billion) is measured against net assets of CN¥18.18 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See 603077 cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Sichuan Hebang Biotechnology Co Ltd Working Capital to Net Assets (2009–2025)
This chart shows how Sichuan Hebang Biotechnology Co Ltd's Working Capital to Net Assets ratio has evolved across 17 annual periods from 2009 to 2025. As of March 2026, the ratio stands at 50.8%, reflecting working capital of CN¥9.23 Billion against net assets of CN¥18.18 Billion CNY. For the complete balance sheet picture, see how large is Sichuan Hebang Biotechnology Co Ltd's balance sheet.
Annual Working Capital to Net Assets for Sichuan Hebang Biotechnology Co Ltd (2009–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Sichuan Hebang Biotechnology Co Ltd from 2009 to 2025, covering 17 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. Check Sichuan Hebang Biotechnology Co Ltd liquidity resilience to evaluate the company's liquid asset resilience ratio.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 45.9% | CN¥8.24 Billion | CN¥17.96 Billion | CN¥12.02 Billion | CN¥3.78 Billion | ▲ +0.5 pp |
| 2024 | 45.4% | CN¥8.63 Billion | CN¥19.01 Billion | CN¥14.00 Billion | CN¥5.37 Billion | ▲ +14.8 pp |
| 2023 | 30.6% | CN¥6.18 Billion | CN¥20.22 Billion | CN¥9.85 Billion | CN¥3.67 Billion | ▲ +0.3 pp |
| 2022 | 30.3% | CN¥5.98 Billion | CN¥19.76 Billion | CN¥9.72 Billion | CN¥3.73 Billion | ▲ +19.9 pp |
| 2021 | 10.4% | CN¥1.52 Billion | CN¥14.64 Billion | CN¥4.64 Billion | CN¥3.12 Billion | ▲ +8.9 pp |
| 2020 | 1.5% | CN¥165.62 Million | CN¥11.31 Billion | CN¥3.32 Billion | CN¥3.15 Billion | ▼ -4.7 pp |
| 2019 | 6.2% | CN¥706.80 Million | CN¥11.45 Billion | CN¥3.49 Billion | CN¥2.78 Billion | ▼ -9.5 pp |
| 2018 | 15.7% | CN¥1.75 Billion | CN¥11.20 Billion | CN¥3.51 Billion | CN¥1.76 Billion | ▼ -4.4 pp |
| 2017 | 20.1% | CN¥2.26 Billion | CN¥11.27 Billion | CN¥3.58 Billion | CN¥1.32 Billion | ▼ -1.1 pp |
| 2016 | 21.1% | CN¥2.28 Billion | CN¥10.78 Billion | CN¥3.61 Billion | CN¥1.33 Billion | ▲ +42.1 pp |
| 2015 | -20.9% | CN¥-1.38 Billion | CN¥6.58 Billion | CN¥2.34 Billion | CN¥3.72 Billion | ▲ +12.1 pp |
| 2014 | -33.0% | CN¥-1.57 Billion | CN¥4.75 Billion | CN¥1.78 Billion | CN¥3.35 Billion | ▼ -52.7 pp |
| 2013 | 19.7% | CN¥647.89 Million | CN¥3.29 Billion | CN¥2.13 Billion | CN¥1.49 Billion | ▼ -23.1 pp |
| 2012 | 42.8% | CN¥1.46 Billion | CN¥3.40 Billion | CN¥2.35 Billion | CN¥895.98 Million | ▲ +57.4 pp |
| 2011 | -14.6% | CN¥-195.47 Million | CN¥1.34 Billion | CN¥922.83 Million | CN¥1.12 Billion | ▲ +28.2 pp |
| 2010 | -42.8% | CN¥-417.04 Million | CN¥974.62 Million | CN¥727.15 Million | CN¥1.14 Billion | ▲ +34.2 pp |
| 2009 | -77.0% | CN¥-567.90 Million | CN¥737.62 Million | CN¥726.64 Million | CN¥1.29 Billion | — |